Novozymes Biopharma is presenting two scientific posters on the manufacturing and use of recombinant albumin in formulation during Peptalk 2011, 10-14 January, San Diego, US.
The posters cover the company's latest research in the use of recombinant human albumin and its ability to address many of the formulation challenges faced by the industry.
The first poster, entitled 'Recombinant human albumin: a multifunctional excipient for stable therapeutic protein formulations', demonstrates the unmatched ability of recombinant albumin to protect therapeutic proteins against chemical and physical degradation.
The second, entitled 'Optimizing Saccharomyces cerevisiae for the rapid development of animal-free biopharmaceutical manufacturing processes', provides insight into the benefits of the yeast strain in the production of recombinant proteins.
The two posters offer protein scientists new insight into formulation and manufacturing, and highlight how recombinant albumin can help optimise current processes.
The latest solutions that help to overcome some of the main challenges associated with the manufacture of protein therapeutics and biologics formulation development are described.
